Schultz AM, Bradac JAThe HIV vaccine pipeline, from preclinical to phase III. AIDS 2001;15 Suppl 5:S147-58
McMichael A, Hanke TThe quest for an AIDS vaccine: is the CD8+ T-cell approach feasible? Nat. Rev. Immunol. 2002;2(4):283-91
The rationale for developing anti-HIV vaccines that stimulate cytotoxic T-lymphocyte responses is given. We argue that such vaccines will work, provided that attention is paid to the development of memory T-cell responses that are strong and preferably activated. Furthermore, the vaccine should match the prevailing virus clade as closely as possible. Vaccines will have to stimulate a wide range of responses, but it is not clear how this can be achieved.
Wee EG, Patel S, McMichael AJ, Hanke TA DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques. J. Gen. Virol. 2002;83(Pt 1):75-80
The minimum requirement for candidate human immunodeficiency virus (HIV) vaccines to enter clinical evaluation in humans should be their demonstrable immunogenicity in non-human primates: induction of antibodies neutralizing primary HIV isolates or elicitation of broad T cell-mediated immune responses. Here, we showed in rhesus macaques that the very same vaccines that had entered clinical trials in Oxford and Nairobi, plasmid pTHr.HIVA DNA and recombinant modified vaccinia virus Ankara MVA.HIVA in a prime-boost protocol (Hanke & McMichael, Nature Medicine 6, 951-955, 2000), induced cellular immune responses specific for multiple HIV-derived epitopes. This was demonstrated by using the intracellular cytokine staining and ELISPOT assays detecting interferon-gamma and pools of peptides employed in the clinical studies. These results have both boosted our expectations for the performance of these vaccines in humans and increased our confidence about the choice of these assays as the primary readouts in the on-going human trials.
Wheeler C, Berkley SInitial lessons from public-private partnerships in drug and vaccine development. Bull. World Health Organ. 2001;79(8):728-34
In recent years, venture capital approaches have delivered impressive results in identifying and funding promising health discoveries and bringing them to market. This success has inspired public sector experiments with 'social venture capital' approaches to address the dearth of affordable treatment and prevention for diseases of the developing world. Employing the same focus on well-defined and measurable objectives, and the same type of connections to pool and deploy resources as their for-profit counterparts, social venture capitalists seek to use the tools and incentives of capitalism to solve one of its biggest failures: the lack of drugs and vaccines for diseases endemic to low-income populations. As part of a larger trend of partnerships emerging in health product donation and distribution, public-private partnerships for pharmaceutical development have led research and development (R&D) efforts to generate more accessible and efficacious products for diseases such as malaria, tuberculosis, and AIDS. In this article, three R&D-focused partnerships are explored: the International AIDS Vaccine Initiative; the Medicines for Malaria Venture; and the newly formed Global Alliance for TB Drug Development. The article highlights key elements essential to the success of these ventures.
Johnston MIHIV/AIDS Vaccine Development: Challenges, Progress and Future Directions. Rev. Med. Virol. 1996;6(3):123-140
HIV vaccine development for the world: an idea whose time has come? AIDS Res. Hum. Retroviruses 1998;14 Suppl 3:S191-6
Page 87 of 87
Board of Directors
Global Funding & Support
Translation & Product Development
Clinical & Epidemiology Research
Global Community Engagement
bnAbs for HIV Prevention
Emerging Infectious Diseases Vaccines and Therapeutics
IAVI in the News
Fact Sheets & Publications
©2020 International AIDS Vaccine Initiative. International AIDS Vaccine Initiative®, IAVI®, and the IAVI logo® are registered trademarks of the International AIDS Vaccine Initiative, Inc.